Structural, magnetic, and hemocompatibility analysis of nickel-neodymium nanoparticles synthesized via laser ablation technique
Materials Chemistry and Physics, vol.363, 2026 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 363
- Publication Date: 2026
- Doi Number: 10.1016/j.matchemphys.2026.132791
- Journal Name: Materials Chemistry and Physics
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, Chimica, Compendex, INSPEC, Academic Search Ultimate (EBSCO), Engineering Source (EBSCO)
- Keywords: Blood compatibility, Microstrain, Nd-Ni spinel ferrite, Stress, Williamson–Hall
- Hakkari University Affiliated: Yes
Abstract
In this work, Nd–Ni ferrite-based nanoparticles were prepared by laser ablation using a nominal Ni0.5Nd0.5Fe2O4 target. Rietveld-type refinement confirmed the formation of a NdFeO3-dominant multiphase ferrite–orthoferrite nanocomposite, with phase fractions of 51 wt% NdFeO3, 45 wt% spinel ferrite, 2.5 wt% NiO, and 1.5 wt% Fe2O3. For the spinel ferrite phase, the lattice parameter, unit cell volume, and average crystallite size were estimated as 8.33 Å, 577.45 Å3, and 35.45 nm, respectively. The Debye–Scherrer and Williamson–Hall analyses were used to estimate the apparent crystallite size, strain, and stress parameters, considering the multiphase nature of the sample. SEM images revealed generally spherical and agglomerated nanoparticles, with particle sizes mainly in the range of 6–10 nm. The FT-IR spectrum exhibited a metal–oxygen vibration band near 537.25 cm−1, whereas no distinct octahedral vibration band was observed around 400 cm−1. The M − H curve exhibited an S- shaped hysteresis loop without complete saturation, reflecting the combined magnetic response of the ferrimagnetic spinel ferrite and weakly magnetic/antiferromagnetic secondary phases. The remanent magnetization and coercive field were found to be 3.925 emu/g and 125.44 Oe, respectively. Blood compatibility tests indicated that the Nd–Ni ferrite-based nanocomposite can be considered hemocompatible up to 3.0 mg/mL according to international standards.